MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
|
|
- Jane Doyle
- 5 years ago
- Views:
Transcription
1 POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder contract. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This guideline is solely for explaining correct procedure reporting and does not imply coverage and reimbursement. DESCRIPTION The spread of tumor cells from the developmental site of origin in the body to other tissue locations is a process called metastasis. An estimated 2% to 5% of all cancers diagnosed may be metastasized carcinoma of unknown primary origin (CUP). Preferred treatment and prognosis is dependent on determining the site of origin of the carcinoma. The CancerTYPE ID is a real-time reverse transcription PCR (RT-PCR) profiling test that compares the RNA expression from formalin-fixed paraffin-embedded (FFPE) tumor tissue from a patient with cancer of unknown primary (CUP) to the expression patterns of a panel of 50 different tumor types and subtypes to identify the most likely primary tissue of origin. There is insufficient evidence to assess the clinical utility of the CancerTYPE ID, and limited evidence to assess its analytical and clinical validity in patients with cancer of uncertain primary to identify the most likely primary tissue of origin. The Tissue of Origin Test is a microarray-based RNA profiling test that compares the RNA expression of formalinfixed paraffin-embedded (FFPE) tumor tissue from a patient with CUP to the expression patterns of a panel of 15 known characterized tumor types (bladder, breast, colorectal, gastric, hepatocellular, kidney, melanoma, non- Hodgkin s lymphoma, non-small cell lung, ovarian, pancreas, prostate, sarcoma, testicular germ cell, and thyroid) to identify the most likely primary tissue of origin. ProOnc TumorSourceDX uses mirview mets technology to identify tissue of origin for a metastatic tumor. RNA is extracted from samples of FFPE tumor sections of unknown primary origin. Developmental origin of tumor is determined using microarray-based mirna expression profiling and a decision tree classification algorithm. The patient population that may be considered for mirview mets testing includes patients with CUP to diagnosis primary origin. In addition, patients with carcinomas of suspected or known primary origin may be considered for mirview mets testing to confirm diagnosis. The RosettaGX Reveal test is a quantitative reverse transcription PCR (qrt-pcr)-based profiling test that measures microrna expression levels in RNA extracted from stained thyroid fine-needle aspiration (FNA) biopsy smears or cell blocks. A proprietary algorithm classifier combines linear discriminant analysis steps and a K Nearest Neighbor classifier step to differentiate thyroid nodules as benign or suspicious for malignancy. In addition, the test measures the hsa-mir-375 marker for medullary carcinoma. To date, the majority of the available studies fail to provide sufficient evidence that gene expression profiling to identify the tissue of origin for cancers lead to improved health outcomes (i.e., clinical utility). Well-designed randomized controlled trials (RCTs) are needed to determine the clinical utility of gene expression profiling to identify the tissue of origin for cancers of unknown primary site compared with traditional clinicopathologic factors to guide medical management and improve clinical outcomes. POLICY HMO, PPO, Individual Marketplace, & Advantage Gene expression profiling to identify the tissue of origin for cancers of unknown primary site (81504, 81540) is non-covered, including but not limited to: CancerTYPE ID ResponseDX Tissue of Origin Test ProOnc TumorSourceDX RosettaGX Cancer Origin Elite
2 o o o CancerTYPE ID (81540) does not require prior authorization. ResponseDX Tissue of Origin Test (81504) does not require prior authorization. All other tests for gene expression profiling to identify the tissue of origin for cancers of unknown primary site are non-covered, including but not limited to: ProOnc TumorSourceDX RosettaGX Cancer Origin HMO, PPO, Individual Marketplace, Advantage Gene expression profiling is considered investigational and not medically necessary as a technique to identify the tissue of origin for cancers of unknown primary site for all indications, including but not limited to: Determining the tissue of origin for a primary tumor; or Determining the tissue of origin for a metastatic tumor. Elite While there is insufficient evidence in the published medical literature to demonstrate the safety, efficacy and longterm outcomes of CancerTYPE ID, CMS requires this test be covered for Elite members with cancer of unknown primary (CUP). To bill for CANCER TYPE ID, please provide the following claim information: For services use CPT code Enter 1 in the Days/Unit field Select the appropriate ICD-10-CM code as listed below (ICD-10 CODES THAT ARE COVERED FOR CANCER TYPE ID FOR ELITE ONLY) While there is insufficient evidence in the published medical literature to demonstrate the safety, efficacy and longterm outcomes of ResponseDX Tissue of Origin Test, CMS requires this test be covered for Elite members with cancer of unknown primary (CUP). To bill for ResponseDX Tissue of Origin Test, please provide the following claim information: For services use CPT code Enter 1 in the Days/Unit field Select the appropriate ICD-10-CM code as listed below (ICD-10 CODES THAT ARE COVERED FOR RESPONSEDX TISSUE OF ORIGIN FOR ELITE ONLY) Paramount expects these tests to ONLY be ordered by the treating physician. CODING/BILLING INFORMATION The appearance of a code in this section does not necessarily indicate coverage. Codes that are covered may have selection criteria that must be met. Payment for supplies may be included in payment for other services rendered. CPT CODES Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffinembedded tissue, algorithm reported as tissue similarity scores Oncology (tumor of unknown origin), mrna, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype ICD-10 CODES THAT ARE COVERED FOR CANCER TYPE ID FOR ELITE ONLY C18.1 Malignant neoplasm of appendix C18.9 Malignant neoplasm of colon, unspecified C22.0 Liver cell carcinoma C22.2 Hepatoblastoma C22.3 Angiosarcoma of liver C22.4 Other sarcomas of liver C22.7 Other specified carcinomas of liver C22.8 Malignant neoplasm of liver, primary, unspecified as to type C22.9 Malignant neoplasm of liver, not specified as primary or secondary C25.2 Malignant neoplasm of tail of pancreas C25.7 Malignant neoplasm of other parts of pancreas C25.8 Malignant neoplasm of overlapping sites of pancreas C25.9 Malignant neoplasm of pancreas, unspecified C33 Malignant neoplasm of trachea C34.01 Malignant neoplasm of right main bronchus
3 C34.02 Malignant neoplasm of left main bronchus C34.11 Malignant neoplasm of upper lobe, right bronchus or lung C34.12 Malignant neoplasm of upper lobe, left bronchus or lung C34.2 Malignant neoplasm of middle lobe, bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus or lung C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung C34.91 Malignant neoplasm of unspecified part of right bronchus or lung C34.92 Malignant neoplasm of unspecified part of left bronchus or lung C43.51 Malignant melanoma of anal skin C43.52 Malignant melanoma of skin of breast C43.59 Malignant melanoma of other part of trunk C45.9 Mesothelioma, unspecified C47.0 Malignant neoplasm of peripheral nerves of head, face and neck C47.9 Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified C48.0 Malignant neoplasm of retroperitoneum C49.0 Malignant neoplasm of connective and soft tissue of head, face and neck C49.9 Malignant neoplasm of connective and soft tissue, unspecified C Malignant neoplasm of upper-outer quadrant of right female breast C Malignant neoplasm of upper-outer quadrant of left female breast C Malignant neoplasm of lower-outer quadrant of right female breast C Malignant neoplasm of lower-outer quadrant of left female breast C Malignant neoplasm of overlapping sites of right female breast C Malignant neoplasm of overlapping sites of left female breast C Malignant neoplasm of unspecified site of right female breast C Malignant neoplasm of unspecified site of left female breast C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C61 Malignant neoplasm of prostate C64.1 Malignant neoplasm of right kidney, except renal pelvis C64.2 Malignant neoplasm of left kidney, except renal pelvis C67.5 Malignant neoplasm of bladder neck C67.9 Malignant neoplasm of bladder, unspecified C76.0 Malignant neoplasm of head, face and neck C77.0 Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes C77.2 Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes C77.3 Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes C77.4 Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes C77.5 Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes C77.8 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions C77.9 Secondary and unspecified malignant neoplasm of lymph node, unspecified C78.01 Secondary malignant neoplasm of right lung C78.02 Secondary malignant neoplasm of left lung C78.5 Secondary malignant neoplasm of large intestine and rectum C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct C79.01 Secondary malignant neoplasm of right kidney and renal pelvis C79.02 Secondary malignant neoplasm of left kidney and renal pelvis C79.2 Secondary malignant neoplasm of skin C79.31 Secondary malignant neoplasm of brain C79.49 Secondary malignant neoplasm of other parts of nervous system C79.51 Secondary malignant neoplasm of bone C79.52 Secondary malignant neoplasm of bone marrow C79.61 Secondary malignant neoplasm of right ovary C79.62 Secondary malignant neoplasm of left ovary C79.89 Secondary malignant neoplasm of other specified sites C80.0 Disseminated malignant neoplasm, unspecified C80.1 Malignant (primary) neoplasm, unspecified C82.57 Diffuse follicle center lymphoma, spleen C84.A7 Cutaneous T-cell lymphoma, unspecified, spleen
4 C84.Z7 Other mature T/NK-cell lymphomas, spleen C84.97 Mature T/NK-cell lymphomas, unspecified, spleen C85.17 Unspecified B-cell lymphoma, spleen C85.27 Mediastinal (thymic) large B-cell lymphoma, spleen C85.87 Other specified types of non-hodgkin lymphoma, spleen C85.97 Non-Hodgkin lymphoma, unspecified, spleen C86.1 Hepatosplenic T-cell lymphoma D01.5 Carcinoma in situ of liver, gallbladder and bile ducts D01.7 Carcinoma in situ of other specified digestive organs D01.9 Carcinoma in situ of digestive organ, unspecified D02.21 Carcinoma in situ of right bronchus and lung D02.22 Carcinoma in situ of left bronchus and lung D03.51 Melanoma in situ of anal skin D03.52 Melanoma in situ of breast (skin) (soft tissue) D03.59 Melanoma in situ of other part of trunk D49.0 Neoplasm of unspecified behavior of digestive system D49.1 Neoplasm of unspecified behavior of respiratory system D49.2 Neoplasm of unspecified behavior of bone, soft tissue, and skin D49.3 Neoplasm of unspecified behavior of breast D49.4 Neoplasm of unspecified behavior of bladder D Neoplasm of unspecified behavior of right kidney D Neoplasm of unspecified behavior of left kidney D49.59 Neoplasm of unspecified behavior of other genitourinary organ D49.6 Neoplasm of unspecified behavior of brain D49.7 Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system D49.89 Neoplasm of unspecified behavior of other specified sites D49.9 Neoplasm of unspecified behavior of unspecified site J91.0 Malignant pleural effusion ICD-10 CODES THAT ARE COVERED FOR RESPONSEDX TISSUE OF ORIGIN FOR ELITE ONLY C18.1 Malignant neoplasm of appendix C18.9 Malignant neoplasm of colon, unspecified C22.0 Liver cell carcinoma C22.2 Hepatoblastoma C22.3 Angiosarcoma of liver C22.4 Other sarcomas of liver C22.7 Other specified carcinomas of liver C22.8 Malignant neoplasm of liver, primary, unspecified as to type C22.9 Malignant neoplasm of liver, not specified as primary or secondary C25.2 Malignant neoplasm of tail of pancreas C25.7 Malignant neoplasm of other parts of pancreas C25.8 Malignant neoplasm of overlapping sites of pancreas C25.9 Malignant neoplasm of pancreas, unspecified C33 Malignant neoplasm of trachea C34.00 Malignant neoplasm of unspecified main bronchus C34.01 Malignant neoplasm of right main bronchus C34.02 Malignant neoplasm of left main bronchus C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung C34.11 Malignant neoplasm of upper lobe, right bronchus or lung C34.12 Malignant neoplasm of upper lobe, left bronchus or lung C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus or lung C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung C43.51 Malignant melanoma of anal skin C43.52 Malignant melanoma of skin of breast C43.59 Malignant melanoma of other part of trunk C45.9 Mesothelioma, unspecified C47.0 Malignant neoplasm of peripheral nerves of head, face and neck C47.9 Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified C48.0 Malignant neoplasm of retroperitoneum
5 C49.0 Malignant neoplasm of connective and soft tissue of head, face and neck C49.9 Malignant neoplasm of connective and soft tissue, unspecified C Malignant neoplasm of upper-outer quadrant of right female breast C Malignant neoplasm of upper-outer quadrant of unspecified female breast C Malignant neoplasm of lower-outer quadrant of right female breast C Malignant neoplasm of lower-outer quadrant of left female breast C Malignant neoplasm of lower-outer quadrant of unspecified female breast C Malignant neoplasm of overlapping sites of right female breast C Malignant neoplasm of overlapping sites of left female breast C Malignant neoplasm of overlapping sites of unspecified female breast C Malignant neoplasm of unspecified site of right female breast C Malignant neoplasm of unspecified site of left female breast C Malignant neoplasm of unspecified site of unspecified female breast C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C56.9 Malignant neoplasm of unspecified ovary C61 Malignant neoplasm of prostate C64.1 Malignant neoplasm of right kidney, except renal pelvis C64.2 Malignant neoplasm of left kidney, except renal pelvis C64.9 Malignant neoplasm of unspecified kidney, except renal pelvis C67.5 Malignant neoplasm of bladder neck C67.9 Malignant neoplasm of bladder, unspecified C76.0 Malignant neoplasm of head, face and neck C77.0 Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes C77.2 Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes C77.3 Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes C77.4 Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes C77.5 Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes C77.8 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions C77.9 Secondary and unspecified malignant neoplasm of lymph node, unspecified C78.00 Secondary malignant neoplasm of unspecified lung C78.01 Secondary malignant neoplasm of right lung C78.02 Secondary malignant neoplasm of left lung C78.5 Secondary malignant neoplasm of large intestine and rectum C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct C79.00 Secondary malignant neoplasm of unspecified kidney and renal pelvis C79.01 Secondary malignant neoplasm of right kidney and renal pelvis C79.02 Secondary malignant neoplasm of left kidney and renal pelvis C79.2 Secondary malignant neoplasm of skin C79.31 Secondary malignant neoplasm of brain C79.51 Secondary malignant neoplasm of bone C79.52 Secondary malignant neoplasm of bone marrow C79.60 Secondary malignant neoplasm of unspecified ovary C79.61 Secondary malignant neoplasm of right ovary C79.62 Secondary malignant neoplasm of left ovary C79.89 Secondary malignant neoplasm of other specified sites C79.9 Secondary malignant neoplasm of unspecified site C80.0 Disseminated malignant neoplasm, unspecified C80.1 Malignant (primary) neoplasm, unspecified C82.57 Diffuse follicle center lymphoma, spleen C84.A7 Cutaneous T-cell lymphoma, unspecified, spleen C84.97 Mature T/NK-cell lymphomas, unspecified, spleen C85.17 Unspecified B-cell lymphoma, spleen C85.27 Mediastinal (thymic) large B-cell lymphoma, spleen C85.87 Other specified types of non-hodgkin lymphoma, spleen C85.97 Non-Hodgkin lymphoma, unspecified, spleen C86.1 Hepatosplenic T-cell lymphoma D01.5 Carcinoma in situ of liver, gallbladder and bile ducts D01.7 Carcinoma in situ of other specified digestive organs D01.9 Carcinoma in situ of digestive organ, unspecified
6 D02.20 Carcinoma in situ of unspecified bronchus and lung D02.21 Carcinoma in situ of right bronchus and lung D02.22 Carcinoma in situ of left bronchus and lung D03.51 Melanoma in situ of anal skin D03.52 Melanoma in situ of breast (skin) (soft tissue) D03.59 Melanoma in situ of other part of trunk D49.0 Neoplasm of unspecified behavior of digestive system D49.1 Neoplasm of unspecified behavior of respiratory system D49.2 Neoplasm of unspecified behavior of bone, soft tissue, and skin D49.3 Neoplasm of unspecified behavior of breast D49.4 Neoplasm of unspecified behavior of bladder D Neoplasm of unspecified behavior of right kidney D Neoplasm of unspecified behavior of left kidney D49.6 Neoplasm of unspecified behavior of brain D49.7 Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system D49.89 Neoplasm of unspecified behavior of other specified sites D49.9 Neoplasm of unspecified behavior of unspecified site J91.0 Malignant pleural effusion TAWG REVIEW DATES: 04/22/2016, 11/14/2017, 07/26/2018 REVISION HISTORY EXPLANATION 04/22/16: Policy created to reflect most current clinical evidence per The Technology Assessment Working Group (TAWG). 11/14/17: Policy reviewed and updated to reflect most current clinical evidence per The Technology Assessment Working Group (TAWG). 07/26/18: Changed title from PG0364 Cancer Type ID to Gene Expression Profiling for Cancers of Unknown Primary Site. Added code Added ResponseDX Tissue of Origin Test (81504) as covered without prior authorization for Elite per CMS guidelines, & non-covered for HMO, PPO, Individual Marketplace, & Advantage. Added ProOnc TumorSourceDX & RosettaGX Cancer Origin tests to policy as non-covered for all product lines. Added required ICD-10 diagnoses codes per CMS guidelines A54188 for CancerTYPE ID. Added required ICD-10 diagnoses codes per CMS guidelines A54198 for ResponseDX Tissue of Origin Test. Policy reviewed and updated to reflect most current clinical evidence per The Technology Assessment Working Group (TAWG). REFERENCES/RESOURCES Centers for Medicare and Medicaid Services, CMS Manual System and other CMS publications and services Ohio Department of Medicaid American Medical Association, Current Procedural Terminology (CPT ) and associated publications and services Industry Standard Review Hayes, Inc.
Corporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More information155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationNeoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationCancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
More informationBRAF Mutation Analysis
Last Review Date: October 13, 2017 Number: MG.MM.LA.38aC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationCEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationAPPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
More informationCLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
More informationCarcinoembryonic Antigen
Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring
More informationANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
More informationCODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
More informationMEDICAL POLICY Acupuncture
POLICY: PG0382 ORIGINAL EFFECTIVE: 12/13/16 LAST REVIEW: 06/12/18 MEDICAL POLICY Acupuncture GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual
More informationIcd 10 code met renal cell
Icd 10 code met renal cell Search 1-10-2015 Free, official coding info for 2018 ICD - 10 -CM N16 - includes detailed rules, notes, synonyms, ICD -9-CM conversion, index and annotation crosswalks, DRG.
More informationIntroduction to ICD-O-3 coding rules
Introduction to ICD-O-3 coding rules Weena Laddachayaporn, MD National Cancer Institute, Bangkok, Thailand ICD-O-3 The International Classification of Diseases for Oncology Is a coding system for primary
More informationModel Policy. Coverage of Proton Therapy
Model Policy Coverage of Proton Therapy Last Revised - February 2019 INTRODUCTION Proton therapy is a technologically advanced method to deliver curative radiation doses to cancerous tumors. The unique
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationSAMPLE. Laboratory Services. An essential coding, billing, and reimbursement resource for laboratory and pathology services ICD-10
Coding and Payment Guide www.optumcoding.com Laboratory Services An essential coding, billing, and reimbursement resource for laboratory and pathology services 2017 ICD-10 A full suite of resources including
More informationAlpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
More informationTable E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
More informationDATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY
Date: 10 th April 2018 DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY Request: 1. Utilization Data of Overseas Beam Therapy and Brachytherapy 2. Diagnoses Data of Overseas Claims for Beam Therapy and Brachytherapy
More informationContractor Information. LCD Information. Local Coverage Determination (LCD): Computerized Axial Tomography of the Chest/Thorax (L34416)
Local Coverage Determination (LCD): Computerized Axial Tomography of the Chest/Thorax (L34416) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationCLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (brentuximab vedotin) MP-035-MD-DE Provider Notice Date: 08/01/2017 Original Effective Date: 09/01/2017 Annual Approval Date:
More informationAlpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Oncologic Genetic Testing Panels MP-074-MD-PA Medical Management Provider Notice Date: 11/15/2018 Issue Date: 12/15/2018 Effective
More informationCLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (Brentuximab Vedotin) MP-035-MD-WV Provider Notice Date: 07/03/2017 Original Effective Date: 08/03/2017 Annual Approval Date:
More informationWLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
More informationAlpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY ADCETRIS (Brentuximab Vedotin) MP-035-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Medical Management Annual
More informationWLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationTruman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
More informationIcd-10 for cancer that spread to the lungs
Icd-10 for cancer that spread to the lungs The Borg System is 100 % Icd-10 for cancer that spread to the lungs Breast cancer metastatic to lymph node; Cancer metastatic to lymph node, adenocarcinoma; Cancer
More informationMEDICAL POLICY Cardiac Event Monitors/ Cardiac Event Detection
POLICY: PG0039 ORIGINAL EFFECTIVE: 10/01/11 LAST REVIEW: 12/12/17 MEDICAL POLICY Cardiac Event Monitors/ Cardiac Event Detection GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationContractor Information. LCD Information. Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Document Information
Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationCrosswalk File of ICD9 Diagnosis Codes to Risk Group Assignment 1-Apr-15
1 1500 MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS 1 1501 MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS 1 1502 MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS 1 1503 MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS 1
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas Circulares.]
More informationAmerican Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
More informationFlorida Cancer Data System STAT File Documentation Version 2019
Florida Cancer Data System STAT File Documentation Version 2019 Field Description NAACCR Item Recoded Patient ID Number 20 Addr at DX - State 80 X County at DX 90 Addr at DX Country 102 X Marital Status
More informationLymphoma Cover Cover. Non-small cell lung Cover Cover. Ovary Cover Cover. Brain Cover Cover. Cervix Cover with exceptions * Cover
POLICY: PG0450 ORIGINAL EFFECTIVE: 11/28/18 LAST REVIEW: MEDICAL POLICY Positron Emission Tomography (PET) Oncology Applications GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationContractor Information. LCD Information. Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Document Information
Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abraxane) Reference Number: CP.PHAR.176 Effective Date: 07.01.15 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationIcd 10 code lung ca with mets to bone
Icd 10 code lung ca with mets to bone 2018 ICD-10 -CM Diagnosis Code C79.9.. C79.9 is a billable/specific ICD - 10 -CM code that can be used to indicate a diagnosis. Metastasis from malignant tumor of
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationKyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationIcd 9 code for small cell lung cancer
1-10-2017 ICD -10-CM Diagnosis Code C34.. The two main types are small cell lung cancer and non- small cell lung cancer.. Convert C34.90 to ICD - 9 -CM. Code History. 25-8-2009 What is the ICD 9 code for
More informationMALIGNANT NEOPLASMS OF THE BREAST MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
MALIGNANT NEOPLASMS OF THE (INC. PAGET S DISEASE) 0 - Nipple and areola 1 - Central portion 2 - Upper-inner quadrant 3 - Lower-inner quadrant 4 - Upper-outer quadrant 5 - Lower-outer quadrant 6 - Axillary
More informationComprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
More informationS2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationMEDICAL POLICY Vitamin D Testing
POLICY: PG0433 ORIGINAL EFFECTIVE: 05/24/18 LAST REVIEW: MEDICAL POLICY Vitamin D Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual
More informationVitamin D Assay Testing For services performed on or after
2018 MEDICARE LOCAL COVERAGE DETERMINATION (LCD) - L36692 CPT CODES: 82306, 82652 Vitamin D Assay Testing For services performed on or after 2-3-2017 DLS TEST CODE AND NAME 49907 (1,25 DIHYDROXY) (CPT
More information82330 CALCIUM; IONIZED. ICD-10 Codes that Support Medical Necessity. ICD-10 Code. Description. A15.0 Tuberculosis of lung
82330 CALCIUM; IONIZED ICD-10 Codes that Support Medical Necessity ICD-10 Code Description A15.0 Tuberculosis of lung A15.4 Tuberculosis of intrathoracic lymph nodes A15.5 Tuberculosis of larynx, trachea
More informationFusilev (levoleucovorin) Document Number: IC-0183
Fusilev (levoleucovorin) Document Number: IC-0183 Last Review Date: 2/1/2018 Date of Origin: 01/02/2014 Dates Reviewed: 08/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016,
More informationComprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
More informationMEDICAL POLICY Children's Intensive Behavioral Service/ Applied Behavioral Analysis (ABA)
POLICY: PG0335 ORIGINAL EFFECTIVE: 12/17/15 LAST REVIEW: 07/10/18 MEDICAL POLICY Children's Intensive Behavioral Service/ Applied Behavioral Analysis (ABA) GUIDELINES This policy does not certify benefits
More informationSerum Iron Studies
190.18 - Serum Iron Studies Serum iron studies are useful in the evaluation of disorders of iron metabolism, particularly iron deficiency and iron excess. Iron studies are best performed when the patient
More informationGamma Glutamyl Transferase
Other Names/Abbreviations GGT 190.32 - Gamma Glutamyl Transferase Gamma glutamyl transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells. Renal tubules, liver, and
More informationChecklist; Anus: Excisional Biopsy Anus: Excisional Biopsy 1/1/ Checklist; Anus: Resection Anus: Resection 1/1/2005
ChecklistTemplateVersions ChecklistTemplateVersion Ckey OfficialName VisibleText RevisionDate Checklist; Adrenal gland: 16.1000043 Resection Adrenal gland: Checklist; Ampulla of 17.1000043 Vater: Ampullectomy
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationJohn R. Marsh Cancer Center
John R. Marsh Cancer Center Lung Program Overview: 2014-2015 Initiatives Lung CT Screening Dr. Gregory Zimmerman In cooperation with The Lung Cancer Steering Committee, Diagnostic Imaging Services at the
More informationCLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Keytruda (pembrolizumab) MP-014-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date: 01/15/2018; 08/01/2017; 06/01/2016
More informationAnnual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationMetastatic esophageal cancer icd 10 code
Metastatic esophageal cancer icd 10 code Gogamz Menu Taxanes are conventional treatment for metastatic breast cancer (MBC); however, the solvents (e.g., ethanol and polyoxyethylated castor oil) employed
More informationMeasure Specifications Measure Description
CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationLiver mets icd-10. Search
Liver mets icd-10 Search 2-3-2012 ICD-10; Risk Adjustment. Mets Liver and lung I am ducts but there does not seem to be anything but stones going on i. ICD-10: C22.0 Short Description: Liver cell carcinoma
More informationProtocol. Microarray-Based Gene Expression Testing for Cancers of Unknown Primary
Microarray-Based Gene Expression Testing for Cancers of Unknown (20454) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/15 Preauthorization No Review Dates: 05/09, 03/10, 01/11, 01/12, 01/13,
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationMEDICAL POLICY Drug Testing
POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each
More informationKhapzory (levoleucovorin) (Intravenous)
Khapzory (levoleucovorin) (Intravenous) Last Review Date: 12/04/2018 Date of Origin: 12/04/2018 Dates Reviewed: 12/2018 Document Number: IC-0408 I. Length of Authorization Coverage will be provided for
More informationCLINICAL MEDICATION POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICATION POLICY Granulocyte Colony Stimulating Factors (G-CSFs) MP-016-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date:
More informationMEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND (TRUS)
MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND 06/16/05, 05/18/06, 03/15/07, 02/21/08 PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationNCD for Fecal Occult Blood Test
NCD for Fecal Occult Blood Test Applicable CPT Code(s): 82272 Blood, occult, by peroxidase activity (e.g., guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal
More informationCPT Codes: The following ICD-10-CM codes support the medical necessity of CPT code 82306:
CPT s: 82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 82652 Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed The following ICD-10-CM codes support the medical necessity of
More informationPembrolizumab (Keytruda )
Last Review Date: March 14, 2017 Number: MG.MM.PH.10f Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationMEDICAL POLICY: Telehealth Services
POLICY: PG0142 ORIGINAL EFFECTIVE: 01/01/08 LAST REVIEW: 12/12/17 MEDICAL POLICY: Telehealth Services GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated
More informationOP-10: ABDOMEN CT USE OF CONTRAST MATERIAL
Description of Measure OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed
More informationSEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
More informationHCPCS Codes (Alphanumeric, CPT AMA) ICD-9-CM Codes Covered by Medicare Program
HCPCS s (Alphanumeric, CPT AMA) 82272 Blood, occult, by peroxidase activity (e.g., guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening ICD-9-CM
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
PROPOSED/DRAFT Local Coverage Determination (LCD): CT of the Head (DL34417) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: This is a Proposed/Draft
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationSubject Cancers in Firefighters and Fire Investigators
If a firefighter or a fire investigator is diagnosed with a prescribed on or after January 1, 1960, and meets the employment duration and additional criteria for the prescribed, then the disease is presumed
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationThe European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
More informationCancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationBiochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval
Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult
More informationPeripheral Nerve Blocks
Last Review Date: April 21, 2017 Number: MG.MM.ME.64v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More information